AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.
Data(s) |
2009
|
---|---|
Resumo |
AA-amyloidosis in the setting of chronic visceral leishmaniasis (VL) has been reported in animal models but documentation in humans is unavailable. Here, we report on a Portuguese man who in 1996 was diagnosed with both human immunodeficiency virus (HIV)-infection and VL. Antiretroviral treatment led to sustained suppression of HIV viremia but CD4+ lymphocytes rose from 8 to only 160 cells/mL. Several courses of antimony treatment did not prevent VL relapses. Renal failure developed in 2006 and renal biopsy revealed AA-amyloidosis. The patient had cryoglobulinemia and serum immune complexes containing antibodies directed against seven leishmanial antigens. Antimony plus amphotericin B, followed by oral miltefosine resulted in a sustained VL treatment response with elimination of circulating Leishmania infantum DNA and CD4+ recovery. The concomitant reduction of serum AA levels and disappearance of circulating leishmanial immune complexes suggests that prolonged VL may lead to AA-amyloidosis in immunocompromised humans. |
Identificador |
http://serval.unil.ch/?id=serval:BIB_16F420BDB2DF isbn:1476-1645[electronic] pmid:19635871 isiid:000268360400006 |
Idioma(s) |
en |
Fonte |
American Journal of Tropical Medicine and Hygiene, vol. 81, no. 2, pp. 209-12 |
Palavras-Chave | #Amphotericin B/therapeutic use; Amyloidosis/complications; Anti-HIV Agents/therapeutic use; Antiprotozoal Agents/therapeutic use; HIV Infections/complications; HIV Infections/drug therapy; Humans; Leishmaniasis, Visceral/complications; Leishmaniasis, Visceral/drug therapy; Male; Meglumine/therapeutic use; Organometallic Compounds/therapeutic use; Young Adult |
Tipo |
info:eu-repo/semantics/article article |